- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Merck plans evaluation of spin-signal MR
GE Healthcare’s gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE’s Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.
GE Healthcare's gas-based MRI imaging strategy may find a home, if tests of the technology by Merck pan out. The pharmaceutical company plans to audition GE's Spin Signal Technology (SST) utilizing hyperpolarized xenon 129 gas for use in assessing its experimental respiratory treatments.
GE Healthcare has granted Merck access to the technology and its novel molecular imaging agent, which allows quantitative MR imaging of the lungs. Merck will assess whether SST is more sensitive than currently available tests used to gauge the function of diseased lungs.GE Healthcare has been looking for viable commercial applications for the technology since acquiring the rights following its merger with Amersham in 2004.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
Can AI Automate BPE Assessment of Dense Breasts on MRI?
April 3rd 2024An MRI-based machine learning model demonstrated a comparable background parenchymal enhancement (BPE) hazard ratio to that of manual BPE assessment for breast cancer, according to a study of over 4,500 women with dense breasts.
